Corbus Pharmaceuticals Holdings, Inc. Restricted Cash and Cash Equivalents
Corbus Pharmaceuticals Holdings, Inc. (CRBP) had Restricted Cash and Cash Equivalents of $158.99 thousand as of 2017-12-31, per its 10-Q filed 2018-11-08.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2018-11-08
- 2017-12-31: Restricted Cash and Cash Equivalents $158.99K.
- 2017-09-30: Restricted Cash and Cash Equivalents $200.00K.
- 2017-06-30: Restricted Cash and Cash Equivalents $200.00K.
- 2017-03-31: Restricted Cash and Cash Equivalents $200.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2017-12-31 | $158.99K 10-Q · filed 2018-11-08 |
| 2017-09-30 | $200.00K 10-Q · filed 2017-11-08 |
| 2017-06-30 | $200.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $200.00K 10-Q · filed 2017-05-09 |
| 2016-12-31 | $200.00K 10-K · filed 2018-03-12 |
| 2015-12-31 | $36.38K 10-K · filed 2017-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |